1. "Jedd Wolchok"
  2. "Naiyer Rizvi"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (4)
  3. Research Letter (1)
Groups
  1. Department of Medicine (11)
  2. GSK Faculty (11)
  3. Melanoma and Immunotherapeutics Service (11)
  4. Solid Tumor Oncology Division (11)
  5. Advanced Practice Providers (6)
  6. Gastrointestinal Oncology Service (6)

More Groups

People
  1. Jedd Wolchok (11)
  2. Naiyer Rizvi (11)
  3. Neil Segal (6)
  4. Ruthann Gordon (6)
  5. Alexander Lesokhin (5)
  6. Blessing Agunwamba (5)

More People

Years
  1. 2019 (1)
  2. 2016 (2)
  3. 2015 (2)
  4. 2014 (4)
  5. 2013 (2)
Publications
  1. Annals of Oncology (2)
  2. Journal of Clinical Oncology (2)
  3. Asia-Pacific Journal of Clinical Oncology (1)
  4. JAMA - Journal of the American Medical Association (1)
  5. Nature Genetics (1)
  6. New England Journal of Medicine (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (2)
  2. Oxford University Press (2)
  3. American Association for the Advancement of Science (1)
  4. American Medical Association (1)
  5. Impact Journals (1)
  6. Massachusetts Medical Society (1)

More Publishers

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
    Meeting Abstract

    Segal, N. H.; Infante, J. R.; Sanborn, R. E.; Gibney, G. T.; Lawrence, D. P.; Rizvi, N.; Leidner, R.; Gajewski, T. F.; Bertino, E.; Sharfman, W. H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Association of pembrolizumab with tumor response and survival among patients with advanced melanoma
    Journal Article

    Ribas, A.; Hamid, O.; Daud, A.; Hodi, F. S.; Wolchok, J. D.; Kefford, R.; Joshua, A. M.; Patnaik, A.; Hwu, W. J.; Weber, J. S.; more...
    JAMA - Journal of the American Medical Association (2016)

    Fulltext@MSK | Save
  • Incidence and management of interstitial lung disease in patients with advanced cancer treated with anti-programmed death receptor 1 ligand pembrolizumab
    Meeting Abstract

    Albano, M.; Gordon, R. A.; Rizvi, N. A.; Wolchok, J. D.
    Oncology Nursing Forum (2015)

    Fulltext@MSK | Save
  • Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    Journal Article

    Rizvi, N. A.; Hellmann, M. D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J. J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T. S. ; more...
    Science (2015)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Classification of current anticancer immunotherapies
    Journal Article

    Galluzzi, L.; Vacchelli, E.; Bravo-San Pedro, J. M.; Buqué, A.; Senovilla, L.; Baracco, E. E.; Bloy, N.; Castoldi, F.; Abastado, J. P.; Agostinis, P.; more...
    Oncotarget (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-programmed death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H.; Callahan, M. K.; Postow, M. A.; Gordon, R.; Seal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Asia-Pacific Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Meeting Abstract

    Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save